These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 730393)

  • 21. Epidemiology of resistance to netilmicin and other aminoglycosides.
    Toscano MA; Russo G; Nicoletti G; Stefani S; Geraci C; Alessandria E
    Chemioterapia; 1986 Jun; 5(3):191-5. PubMed ID: 3719853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of Malassezia pachydermatis to aminoglycosides.
    Silva FA; Conde-Felipe M; Rosario I; Ferrer O; Real F; Déniz S; Acosta F; Padilla D; Acosta-Hernández B
    Mycoses; 2017 Dec; 60(12):796-799. PubMed ID: 28925032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Netilmicin: in-vitro activity compared with that of other aminoglycosides against Serratia marcescens.
    Langstaff D; Schueler S; Righter J
    J Antimicrob Chemother; 1983 Feb; 11(2):187-9. PubMed ID: 6339461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of carbenicillin - aminoglycoside and of cephalothin-aminoglycoside combinations against enterococci in vitro.
    Klastersky J; Daneau D
    Pathol Biol (Paris); 1975 May; 23(5):345-8. PubMed ID: 1105331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of carbenicillin, ticarcillin, sisomicin and netilmicin alone and in combination against Pseudomonas aeruginosa.
    Watanakunakorn C; Glotzbecker C
    Chemotherapy; 1978; 24(6):343-6. PubMed ID: 100282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin.
    Hale DC; Jenkins R; Matsen JM
    Am J Clin Pathol; 1980 Sep; 74(3):316-9. PubMed ID: 6447998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of pseudomonas to four beta-lactamantibiotics (ampicillin, cephalothin, carbenicillin, piperacillin), to four aminoglycosides (kanamycin, amikacin, gentamicin, tobramycin) and to colimycin.
    Hoogkamp-Korstanje JA; Westerdaal NA
    Chemotherapy; 1979; 25(1):48-53. PubMed ID: 253637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa.
    Omri A; Ravaoarinoro M; Poisson M
    J Antimicrob Chemother; 1995 Oct; 36(4):631-9. PubMed ID: 8591937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amikacin and netilmicin resistance in Pseudomonas aeruginosa: incidence and transfer.
    Knothe H; Krcméry V
    Chemotherapy; 1979; 25(1):23-9. PubMed ID: 105839
    [No Abstract]   [Full Text] [Related]  

  • 30. Compiled data on aminoglycoside, foremost netilmicin susceptibility of bacterial strains.
    Juhlin I; Tunevall G
    Scand J Infect Dis Suppl; 1980; Suppl 23():39-44. PubMed ID: 6782657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro study of the synergistic effect of cefotiam- aminoglycoside combinations on strains of low susceptibility to this cephalosporin].
    Husson MO; Izard D; Leclerc H
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):466-8. PubMed ID: 3911141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some properties of Plesiomonas shigelloides treated with aminoglycosides.
    Hostacká A; Ciznár I
    Folia Microbiol (Praha); 2003; 48(5):659-63. PubMed ID: 14976725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of cefotiam combinations against Enterobacteriaceae moderately susceptible or resistant to this new cephalosporin.
    Husson MO; Izard D; Leclerc H
    Drugs Exp Clin Res; 1986; 12(4):325-7. PubMed ID: 3459642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A laboratory assessment of the activities of four aminoglycosides.
    Schrire L; Robinson RG; Koornhof HJ
    S Afr Med J; 1984 Jun; 65(23):922-4. PubMed ID: 6427946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring.
    Agence française de sécurité sanitaire des produits de santé
    Med Mal Infect; 2012 Jul; 42(7):301-8. PubMed ID: 22770656
    [No Abstract]   [Full Text] [Related]  

  • 37. Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium.
    Vanhoof R; Hubrechts JM; Nyssen HJ; Roebben E
    Eur J Clin Microbiol Infect Dis; 1988 Apr; 7(2):183-5. PubMed ID: 3134209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of amikacin, gentamicin and tobramycin combined with carbenicillin or ticarcillin against Pseudomonas aeruginosa in vitro.
    Meitert E; Petrescu AM; Chiru M
    Arch Roum Pathol Exp Microbiol; 1985; 44(2):127-36. PubMed ID: 3938268
    [No Abstract]   [Full Text] [Related]  

  • 39. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
    Noone P
    Drugs; 1984 Jun; 27(6):548-78. PubMed ID: 6376062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invitro comparative evaluation of aminoglycosides at a cancer centre.
    Biswas SK; Kelkar RS
    Indian J Cancer; 2002; 39(4):135-8. PubMed ID: 12928571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.